WO2014088386A1 - Composiciones metformina-orlistat - Google Patents
Composiciones metformina-orlistat Download PDFInfo
- Publication number
- WO2014088386A1 WO2014088386A1 PCT/MX2013/000133 MX2013000133W WO2014088386A1 WO 2014088386 A1 WO2014088386 A1 WO 2014088386A1 MX 2013000133 W MX2013000133 W MX 2013000133W WO 2014088386 A1 WO2014088386 A1 WO 2014088386A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- metformin
- orlistat
- compositions according
- tablets
- silicon dioxide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to compositions of a hypoglycemic agent and an inhibitor of gastric and pancreatic lipases in the intestine, particularly combinations of Metformin and Orlistat, useful for the prevention and treatment of obesity and overweight.
- Diabetes is a chronic disease, which occurs when the pancreas does not produce enough insulin, or when the body cannot effectively use the insulin it produces. This leads to hyperglycemia; altered lipid, carbohydrate and protein metabolism; and high risk of vascular complications.
- Type 2 diabetes mellitus (T2DM) formerly called non-insulin dependent or adult diabetes is found in 90% of people with diabetes worldwide and is a global health problem.
- the World Health Organization publishes on its website that 346 million people worldwide have diabetes and 3.4 million people died due to the consequences of high blood sugar levels in 2004.
- a recent study conducted taking Information from 91 countries reported that the prevalence of diabetes among adults was 6.4%, affecting 285 million adults in 2010, and will increase to 7.7% and 439 million adults by 2030. In Mexico, the prevalence of diabetes among adults of an age of 20-79 years was estimated at 10.1% in 2010 and 13.3% in 2030. In addition, this condition leads to causes of death in that country.
- metformin is a biguanide that reduces liver glucose production, increases glucose absorption and use in skeletal muscle and reduces carbohydrate absorption.
- other non-glycemic benefits attributed to metformin include improved lipids with moderate weight loss or no weight gain, as well as improved vascular reactivity, and endothelial and micro vascular function.
- Metformin is mainly absorbed in the small intestine, has an oral bioavailability of 50-60% under fasting conditions, its plasma protein binding is insignificant, as shown by its very highly evident volume of distribution.
- Orlistat irreversibly inhibits gastric and pancreatic lipases by preventing the collapse of dietary fat to fatty acids and glycerols, therefore, decreases the absorption of fat and respectively increases its excretion in feces up to 30% of dietary fat. Together with a low-calorie diet in obese individuals, it produces a moderate but consistent weight loss. In a study in patients with type 2 diabetes treated with metformin orlistat or placebo was added, after 1 year of treatment, orlistat increases weight loss and improves glycemic control, serum lipid levels, and blood pressure in obese patients with type 2 diabetes who are treated with metformin.
- metformin-orlistat appears to be safe in acute and chronic treatment, orlistat has a bioavailability of less than 5% when administered orally and is only detectable in plasma by mass spectrometry-liquid chromatography or mass spectrometry -Gas chromatography with a low detection limit. Practically, 97% of orlistat is excreted in feces.
- compositions are described pharmaceuticals comprising diethylpropion, metformin, orlistat and at least one pharmaceutically acceptable carrier, as well as methods of treating patients suffering from obesity or requiring weight loss.
- compositions comprising bupropion, metformin, orlistat and at least one pharmaceutically acceptable carrier are also described, as well as a method of treating patients suffering from obesity or requiring weight loss.
- a hypoglycemic agent such as metformin
- an irreversible inhibitor of gastric and pancreatic lipases in the intestine such as orlistat
- a second object is to provide a pharmaceutical composition containing both drugs in a single pharmaceutical form, such that it allows easy administration and therefore improves the patient's attachment to their treatment.
- Table 1 Demographic characteristics of healthy Mexican volunteer subjects. Data are presented as mean ⁇ standard deviation. Table 2. Pharmacokinetic parameters obtained with 500 mg tablets of metformin alone and combined with 60 mg of orlistat after single dose administration in 26 healthy Mexican volunteers. Data are presented as mean ⁇ standard deviation. The coefficient of variation in the percentage is shown in parentheses. standard deviation. The coefficient of variation in the percentage is shown in parentheses.
- Table 3 Relative bioavailability of metformin combined with orlistat (B) in relation to metformin alone (A). The results are provided as 90% confidence intervals for Cmax and the area under the curve (AUC). In addition, the table shows the probability to obtain the values outside the fixed limits and the power. The limits were set within 80-125%. Table 1
- FIG. 1 Heart rate, blood pressure, respiratory rate and otic temperature measured after a single dose of 500 mg of metformin or 500 mg of metformin plus 60 mg of orlistat. Data are presented as mean ⁇ standard deviation of 26 healthy volunteers.
- the present invention allows to determine that the co-administration of orlistat has no influence on the pharmacokinetics of metformin, with which it is possible to ensure that orlistat is an adjuvant drug useful for metformin activity in producing weight loss and improving glycemic control, levels of serum lipids and blood pressure in obese patients with type 2 diabetes.
- compositions of the present invention comprise between 200 and 600 mg of metformin and between 40 and 100 mg of Orlistat, in addition to 10 to 15% of the total weight of the composition, of one or more pharmaceutically acceptable excipients.
- Oral dosage forms are the preferred compositions for use in the present invention and which are known for such administration, for example tablets, coated tablets, capsules, microspheres and granules.
- the pharmaceutically acceptable excipients used in the preparation of the compositions are those known for each form.
- the capsules and tablets can be prepared from a mixture of the active agents with diluting agents such as calcium phosphate, mannitol, microcrystalline cellulose, lactose, DC mannitol, mannitol powder, sorbitol, isomalt, disintegrating agents such as corn starch, crospovidone, croscarmellose sodium, lubricating agents such as magnesium stearate, sodium stearyl fumarate, talcum, sodium lauryl sulfate, binders such as polyvinylpyrrolidone, hydroxypropyl methylcellulose (any substitution), gum arabic, hydroxypropylcellulose (of any substitution), grenetina, hydrolyzed grenetina, sliding agents such as colloidal silicon dioxide, talc, stearic acid and the like.
- diluting agents such as calcium phosphate, mannitol, microcrystalline cellulose, lactose, DC mannitol, mannitol powder, sorbi
- the tablets may include an aesthetic cover of hydroxypropylmethylcellulose phthalate, polyvinyl alcohol, polymethacrylates, Opadry II, Nutrateric, Acryleze, Sureteric or Eudragit, in the same way, soft and / or hard gelatin capsules can be prepared from the mixture of the appropriate assets and excipients, or with granules made according to known techniques and from the compositions described herein.
- Example 1 Composition of 500 mg of metformin and 60 mg of Orlistat in capsules.
- Dissolve in grenetine water, glycerin and gum arabic add a part of colloidal silicon dioxide, form a white viscous suspension, sift orlistat and a part of colloidal silicon dioxide, mix and granulate with the previous suspension, dry in fluid bed at a temperature of 30 ° C to 35 ° C, coated granules are formed.
- Example 2 Composition of 300 mg of metformin and 40 mg of Orlistat in tablet
- the tablets are prepared using the following method: Dissolve in hydrolyzed grenetine water, dissolve glycerin and gum arabic, add a part of colloidal silicon dioxide, form a viscous suspension, sift orlistat and a part of colloidal silicon dioxide, mix and granulate with the previous suspension, dry in a fluid bed. Mix with metformin hydrochloride and mannitol, lubricate With sodium stearyl fumarate and a part of colloidal silicon dioxide, finally compress.
- Example 3 Composition of 500 mg of metformin and 60 mg of orlistat in coated tablet
- compositions object of the present invention are tested in the clinical study described below, where it is evidenced that the compositions object of the present invention comply with the pharmacological effects for the treatment of obesity and overweight.
- Registration criteria also excluded subjects who had any prescription of drug within a period of 2 weeks prior to entering the study or who had consumed xanthines, alcohol, grilled foods or grapefruit juice 72 hours before or during the experiment ; nor were smokers, pregnant women and those with a clinical history of hypersensitivity to medications, food or environmental substances included.
- the experimental protocol was designed in accordance with the general ethical principles described in the Declaration of Helsinki. The protocol for this study, as well as the informed consent documents were completely reviewed and approved by the Ethics Committee of Biomagno, SA de C, V. with the number 02-LTSF-03- MTN / RLT-11 in April, 2011.
- Sample preparation involved a separation with acetonitrile and dichloromethane. 0.5 mL of plasma were added to 1.5 mL of acetonitrile. The mixture was stirred at full speed for 30 seconds and centrifuged at 2000 rpm for 10 minutes. The supernatant was mixed with 1.5 mL of dichloromethane and the new mixture was stirred once more and centrifuged under the conditions mentioned in the previous step. Then, 50 ⁇ of supernatant was injected into the chromatographic system. A calibration curve includes the following concentration points: 0.05, 0.1, 0.2, 0.5, 1 and 1.5 pg / mL. Control samples were prepared with human plasma as a biological matrix and appropriate amounts of drug to obtain concentrations of 0.15, 0.4 and 1.2 g / mL.
- High performance liquid chromatography coupled to an ultraviolet detector was used to determine plasma metformin concentrations.
- the chromatographic system consisted of a high resolution liquid chromatograph (Waters corporation) formed for a model 515 pump, a model 717 auto sampler tray, a model 2487 UV detector and Empower 2.0 software for data analysis. The separation was performed on a silica column Resolve 50 mm long, 3.9 mm internal diameter and 90A particle size, using a phase 0.03 M (25:75 v / v) basic mono sodium acetonitrile / phosphate cell with a flow rate of 1.2 mL / min.
- the temperature of the auto sampler tray was 4 ° C and the retention time of metformin was 3.5 - 4.5.
- the absorbance was read at 234 nm. This method was developed and validated for specificity, sensitivity, linearity recovery, precision, accuracy, stability and robustness in our laboratory according to the specifications of NOM-177-SSA1-1998. In this regard, the quantification of metformin was not interfered with by acetaminophen, acetylsalicylic acid, salicylic acid, ibuprofen or heparin.
- the accuracy of the control samples at 0.15, 0.4 and 1.2 pg / mL concentrations was 8%, 3% and 1.75%, respectively.
- the intravaluation coefficient of variation was 4.15%, 3.28% and 2.40%, respectively; and the coefficient of variation between appraisals was 3.46%, 10.25% and 6.75%, respectively. No significant degradation of metformin was observed during the freeze and thaw cycles, short and long storage or processing conditions.
- the sample size was calculated based on a cross design with data transformed by logarithm, considering a coefficient of intra individual variation of 20%, a power of 80% and a level of significance of 5%, according with Chow and Wang. Under these conditions, the calculated sample size was 18 volunteers; Thus, taking into account potential withdrawals and dropouts, we registered 26 volunteers.
- the plasma metformin concentration curves against time were constructed for each volunteer and for each formulation. The highest plasma concentration observed and the corresponding time was defined as the C max and T max values, respectively.
- the elimination rate constant (Ke) was obtained by linear regression of the slope of best adjustment of the linear logarithmic linear decline in plasma concentrations against the time profile.
- the half-life (t 1 2 ) was obtained as 0.693 / Ke.
- the area under the plasma concentration curve at the last quantifiable concentration (C t ) at time t (AUC 0. t ) was determined by linear trapezoidal integration.
- the AUC extrapolated to infinity (AUC 0. -) was calculated as AUC 0 _ t + C t / Ke.
- the pharmacokinetic parameters were generated using WinNonlin Professional software version 2.0 (Pharsight, Palo Alto, CA, USA). To assess bioequivalence, in order not to establish any pharmacokinetic interaction, an analysis of variance (ANOVA) was used for a cross-study design considering the sequence, period, and effects of treatment.
- ANOVA analysis of variance
- the values of AUC and C max for each volunteer were logarithmically transformed and the relations between both formulations were calculated [logarithm (AUC 2 4h B / AUC 2 4h A ) and logarithm (C max B / C m ax A )]. Then, the mean and 90% Cl of the AUC 24 h and C max ratios were obtained.
- the bioequivalence between metformin alone and metformin combined with orlistat was determined when 90% of Cl of these two parameters were between 0.8 and 1.25 and when p ⁇ 0.05 after a unilateral hypothesis test by Schuirmann.
- the anthropometric characteristics of 26 Mexican volunteers finally included in this study were between 21 and 40 years old, where 50% were women.
- the body weight range was between 49 and 8 ⁇ Kg; the height between 1.47 and 1.81 m and the range of body mass index was between 20.5 and 27.6 Kg / m 2 .
- the mean ⁇ standard deviation of these and other parameters are shown in Table 1.
- the values obtained by electrocardiogram, blood count, blood chemistry, drug abuse detection, general urine test, and hepatitis and HIV tests threw normal values for all volunteers (data not shown); in this way verifying your healthy condition.
- volunteers were monitored for their vital signs.
- Figure 1 shows that heart rate (50-100 beats / min), blood pressure (50-90 / 84-129 mmHg), respiratory rate (14-25 breaths / min) and otic temperature (36-37.8 ° C) they were within normal values throughout the study. In addition, there was no statistical difference in vital signs due to treatment and it was demonstrated by repeated bilateral ANOVA measures.
- the plasma-time concentration curves of both formulations show that the concentration of plasma metformin decreased multiexponentially after the peak time of the concentration ( Figure 2).
- the mean ⁇ standard deviation of metformin tablets and metformin capsules plus orlistat were 1.39 ⁇ 0.44 and 1.38 ⁇ 0.48 Mg / mL for Cmax; and 7.59 ⁇ 3.17 and 7.80 ⁇ 2.83 gh / mL for AUC 24h , respectively.
- These and other pharmacokinetic parameters not considered for the determination of bioequivalence are shown in Table 2.
- the bioequivalence analysis by two unilateral hypothesis tests of Schuirmann in both metformin formulations showed that 90% of Cl for Cmax and AUC 24h were found. within 80% and 125% with a probability of exceeding any limit less than 0.05 (Table 3).
- the ANOVA analysis showed that there was no evidence of variability for the sequence, formulation period in the pharmacokinetic parameters.
- metformin-orlistat was slightly higher than metformin alone, the pharmacokinetic results obtained in the current study showed conclusive data regarding therapeutic equivalence since the comparison between the test formulation, metformin-orlistat, and the formulation of reference, metformin, for Cmax and AUC 2 4h showed percentages that fell on the equivalence scale.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015545409A JP2016501227A (ja) | 2012-12-03 | 2013-11-01 | メトホルミン−オルリスタット組成物 |
US14/648,992 US20150342921A1 (en) | 2012-12-03 | 2013-11-01 | Metformin-orlistat compositions |
EP13860230.5A EP2926813A4 (en) | 2012-12-03 | 2013-11-01 | METFORMIN-Orlistat COMPOSITIONS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2012014070A MX2012014070A (es) | 2012-12-03 | 2012-12-03 | Composiciones metformina-orlistat. |
MXMX/A2012/014070 | 2012-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014088386A1 true WO2014088386A1 (es) | 2014-06-12 |
Family
ID=50883733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/MX2013/000133 WO2014088386A1 (es) | 2012-12-03 | 2013-11-01 | Composiciones metformina-orlistat |
Country Status (5)
Country | Link |
---|---|
US (1) | US20150342921A1 (es) |
EP (1) | EP2926813A4 (es) |
JP (1) | JP2016501227A (es) |
MX (1) | MX2012014070A (es) |
WO (1) | WO2014088386A1 (es) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070060532A1 (en) | 2004-03-12 | 2007-03-15 | Fournier Laboratories Ireland Limited | Use of metformin and orlistat for the treatment or prevention of obesity |
US20100113581A1 (en) | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
US20100113580A1 (en) | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4432757A1 (de) * | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
-
2012
- 2012-12-03 MX MX2012014070A patent/MX2012014070A/es unknown
-
2013
- 2013-11-01 EP EP13860230.5A patent/EP2926813A4/en not_active Withdrawn
- 2013-11-01 JP JP2015545409A patent/JP2016501227A/ja active Pending
- 2013-11-01 WO PCT/MX2013/000133 patent/WO2014088386A1/es active Application Filing
- 2013-11-01 US US14/648,992 patent/US20150342921A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070060532A1 (en) | 2004-03-12 | 2007-03-15 | Fournier Laboratories Ireland Limited | Use of metformin and orlistat for the treatment or prevention of obesity |
US20100113581A1 (en) | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
US20100113580A1 (en) | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
Also Published As
Publication number | Publication date |
---|---|
US20150342921A1 (en) | 2015-12-03 |
MX2012014070A (es) | 2014-06-23 |
JP2016501227A (ja) | 2016-01-18 |
EP2926813A4 (en) | 2016-05-25 |
EP2926813A1 (en) | 2015-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7442095B2 (ja) | ベータ-ヒドロキシブチレート及びブタンジオールのs-エナンチオマー並びにその使用方法 | |
AU2015222754B2 (en) | Compositions and methods for the reduction or prevention of hepatic steatosis | |
Levy et al. | Effect of activated charcoal on aspirin absorption in man Part I | |
EP2646031B9 (en) | Increasing drug bioavailability in naltrexone therapy | |
JP2018118914A (ja) | 神経変性疾患の改善用医薬 | |
ES2635763T3 (es) | Composición de complemento nutricional | |
WO2021109511A1 (zh) | 一种抗疲劳的组合物及其制备方法 | |
WO2015161448A1 (en) | Ornithine-containing or aspartate-containing compositions and the uses thereof | |
Leary et al. | Iron pharmacokinetics in women with iron deficiency anaemia following a single oral dose of a novel formulation of tardyferon (Prolonged release ferrous sulphate) | |
Hurwitz et al. | Gastric function in the elderly: effects on absorption of ketoconazole | |
JP5984328B2 (ja) | 独活葛根湯エキス配合剤 | |
WO2014088386A1 (es) | Composiciones metformina-orlistat | |
EA008765B1 (ru) | Антигриппозное средство | |
CN106349318A (zh) | 一种五环三萜化合物在制备治疗肥胖症药物中的应用 | |
Noh et al. | A single-dose, crossover study comparing the pharmacokinetics and pharmacodynamics of two formulations of metformin in healthy volunteers | |
Neelamegarajan | Formulation Design, Development and Invitro Evaluation of Fast Dissolving Tablets of Sitagliptin by Direct Compression Method | |
JP2005289906A (ja) | 医薬組成物 | |
CN105920017B (zh) | 一种治疗单纯性肥胖症的药物组合物及其用途 | |
WO2015087823A1 (ja) | 炭酸塩を含む口腔内崩壊錠剤用組成物及び口腔内崩壊錠剤 | |
KR20060116082A (ko) | 비타민 c 및 감기 치료제를 함유하는 이중정 제형 및 그의제조방법 | |
CN106880603A (zh) | 一种含有托匹司他的口腔崩解片及其制备方法 | |
Pandey et al. | FORMULATION DEVELOPMENT AND EVALUATION OF FAST DISSOLVING ACELOFENAC TABLETS | |
RU2543322C1 (ru) | Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения | |
AU2022280757A1 (en) | Tizanidine liquid preparation and use thereof | |
US20240148703A1 (en) | Tizanidine liquid preparation and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13860230 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015545409 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14648992 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013860230 Country of ref document: EP |